A Retrospective Chart Review: Current Status of Patients with mood instability and Medical Care in Japan

UMIN ID: UMIN000054003

Registered date:12/04/2024

Basic Information

• Recruitment status: Pending
• Health condition(s) or Problem(s) studied: Borderline Personality Disorder
• Date of first enrollment: 2024/04/12
• Target sample size: 80
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: Proportion of treatment by treatment type for patients with BPD
• Secondary Outcome: Proportion of patients with core symptoms of BPD at the first visit at the study sites Proportion of types of core symptoms in patients with BPD at the time of BPD diagnosis at the study sites Period from the first visit to BPD diagnosis Proportion of patients with psychiatric disorders after BPD diagnosis Proportion of patients using medical resource after BPD diagnosis and types of medical resource Proportion of patients using social resource after BPD diagnosis and types of social resource Proportion of family members (genetically related 1st to 4th degree relatives) with psychiatric disorders that became apparent before and after the patient's BPD diagnosis Proportion of patients showing improvement, exacerbation, and unchanging of symptoms Proportion of patients with BPD who have gone into remission Proportion of patients who achieved social reintegration after BPD diagnosis Proportion of patients with BPD relapse to patients with BPD who have gone into remission Proportion of patients with BPD who have attempted suicide Proportion of patients who have discontinued treatment due to patient's circumstances Patient background

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1)Patients with BPD who see the physicians planning this study, including Boehringer Ingelheim Co., Ltd. Employees, the members of the steering committee and advisors 2)Patients who had participated in research studies involving interventions during the target period of data collection 3)Patients judged to be inappropriate by the principal investigator or sub-investigator for some reasons

Related Information

• Primary Sponsor: Nippon Boehringer Ingelheim Co., Ltd. (NBI: Sponsor)
• Source(s) of Monetary Support: Nippon Boehringer Ingelheim Co., Ltd. (NBI: Sponsor)